Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC. Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start.
Ayuda Buscar en la ayuda Buscar en la ayuda Evaluating the prognostic role of glucose‑to‑lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in frst line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Hatice Bolek [1] ; Omer Faruk Kuzu [8] ; Elif Sertesen Camoz [9] ; Saadet Sim [2] ; Serhat Sekmek [10] ; Hilal Karakas [10] ; Selver Isık [3] ; Murat Günaltılı [11] ; Aysun Fatma Akkus [4] ; Deniz Tural [12] ; Cagatay...
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
